Pulmonx - יחס שווי חברה להכנסות LUNG

Pulmonx Corporation (LUNG) minimizes production risks by utilizing multiple contract manufacturing sites for component fabrication. This complements the success of the Zephyr minimally invasive systems, which have become the benchmark for emphysema therapy. The company's price-to-sales multiple reflects the current market valuation, where the value has stabilized at 1382.41. Business stability is ensured by a California-based final assembly plant featuring automated cleanrooms.
LUNG (pulmonx.com): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Innovative Zephyr valves for emphysema treatment drive the high market value of Pulmonx Corporation (LUNG), which is reflected in the 1382.41 metric. This ratio compares the enterprise value (EV) to revenue, excluding the impact of leverage; analyzing the EV-to-sales ratio on GURU.Markets allows for an assessment of how much the market is currently willing to pay a premium for every dollar of the company's revenue.